JP2025503961A - 脂肪酸のリンパ放出組成物並びにリンパ組み込み及び全身疾患治療のためのその使用 - Google Patents

脂肪酸のリンパ放出組成物並びにリンパ組み込み及び全身疾患治療のためのその使用 Download PDF

Info

Publication number
JP2025503961A
JP2025503961A JP2024544420A JP2024544420A JP2025503961A JP 2025503961 A JP2025503961 A JP 2025503961A JP 2024544420 A JP2024544420 A JP 2024544420A JP 2024544420 A JP2024544420 A JP 2024544420A JP 2025503961 A JP2025503961 A JP 2025503961A
Authority
JP
Japan
Prior art keywords
acid
hydroperoxy
etepa
composition
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024544420A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503961A5 (https=
Inventor
リチャード, プレストン メイソン,
リチャード ルイス ダンバー,
Original Assignee
アマリン ファーマシューティカルズ アイルランド リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アマリン ファーマシューティカルズ アイルランド リミテッド filed Critical アマリン ファーマシューティカルズ アイルランド リミテッド
Publication of JP2025503961A publication Critical patent/JP2025503961A/ja
Publication of JP2025503961A5 publication Critical patent/JP2025503961A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23JPROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J7/00Phosphatide compositions for foodstuffs, e.g. lecithin
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12Fatty acids or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024544420A 2022-01-26 2023-01-26 脂肪酸のリンパ放出組成物並びにリンパ組み込み及び全身疾患治療のためのその使用 Pending JP2025503961A (ja)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US202263303383P 2022-01-26 2022-01-26
US202263303365P 2022-01-26 2022-01-26
US63/303,365 2022-01-26
US63/303,383 2022-01-26
US202263304042P 2022-01-28 2022-01-28
US63/304,042 2022-01-28
US202263334071P 2022-04-22 2022-04-22
US202263334065P 2022-04-22 2022-04-22
US63/334,065 2022-04-22
US63/334,071 2022-04-22
US202263340304P 2022-05-10 2022-05-10
US202263340292P 2022-05-10 2022-05-10
US63/340,304 2022-05-10
US63/340,292 2022-05-10
US202263342509P 2022-05-16 2022-05-16
US63/342,509 2022-05-16
US202263348908P 2022-06-03 2022-06-03
US63/348,908 2022-06-03
PCT/US2023/011651 WO2023146984A1 (en) 2022-01-26 2023-01-26 Lymph-releasing compositions of fatty acids and uses thereof for lymphatic incorporation and systemic disease treatment

Publications (2)

Publication Number Publication Date
JP2025503961A true JP2025503961A (ja) 2025-02-06
JP2025503961A5 JP2025503961A5 (https=) 2026-02-03

Family

ID=87472560

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024544420A Pending JP2025503961A (ja) 2022-01-26 2023-01-26 脂肪酸のリンパ放出組成物並びにリンパ組み込み及び全身疾患治療のためのその使用

Country Status (10)

Country Link
US (1) US20240165066A1 (https=)
EP (1) EP4468884A4 (https=)
JP (1) JP2025503961A (https=)
KR (1) KR20240142470A (https=)
AU (1) AU2023213684A1 (https=)
CA (1) CA3248854A1 (https=)
IL (1) IL314467A (https=)
MA (1) MA66915A1 (https=)
MX (1) MX2024009147A (https=)
WO (1) WO2023146984A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3278665T (pt) * 2009-04-29 2020-11-19 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica estável e métodos de utilização das mesmas
US12433864B2 (en) 2019-06-03 2025-10-07 Migal Galilee Research Institute Ltd. 5,6-diHETE lactone for treatment of microvascular dysfunction
GB202400712D0 (en) * 2024-01-18 2024-03-06 Northwood Consultants Ltd Anti-inflammatory composition and use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3069322A (en) * 1958-05-28 1962-12-18 Bergstrom Sune Pge and pgf
SE8604117D0 (sv) * 1986-09-29 1986-09-29 Kabivitrum Ab Composition
US5262168A (en) * 1987-05-22 1993-11-16 The Liposome Company, Inc. Prostaglandin-lipid formulations
US5262437A (en) * 1990-12-10 1993-11-16 Allergan, Inc. Homo-prostaglandin derivatives as ocular hypotensives
US6077525A (en) * 1998-04-10 2000-06-20 The George Washington University Use of conjugated linoleic acids
JP2005529728A (ja) * 2002-06-18 2005-10-06 マーテック・バイオサイエンシーズ・コーポレーション 水溶液中の油の安定エマルジョンおよびその製造方法
TWI365716B (en) * 2003-12-02 2012-06-11 Suntory Holdings Ltd Oil or fat and oil compositions containing phospholipids and a long-chain polyunsaturated fatty acid supply compound, and food using same
US7893106B2 (en) * 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
US20070042008A1 (en) * 2005-08-18 2007-02-22 Bodybio, Inc. Compositions containing phosphatidylcholine and essential fatty acids
US20090320148A1 (en) * 2006-01-31 2009-12-24 Martek Biosciences Corporation Oxylipins from stearidonic acid and gamma-linolenic acid and methods of making and using the same
ATE549014T1 (de) * 2006-09-05 2012-03-15 Q P Corp Prostaglandin-fettemulsion, verfahren zu ihrer herstellung, verfahren zu ihrer stabilisierung und emulgierendes mittel
WO2011060084A1 (en) * 2009-11-10 2011-05-19 MyCell Holdings Limited Stabilized formulations of fatty acids
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
MX372724B (es) * 2012-12-24 2020-06-19 Qualitas Health Inc Formulaciones de acido eicosapentaenoico (epa).
MY185428A (en) * 2015-01-21 2021-05-19 Mochida Pharm Co Ltd Self-emulsifying composition of ?-3 fatty acid
CA2974495C (en) * 2015-01-21 2023-05-23 Mochida Pharmaceutical Co., Ltd. .omega.-3 fatty acid self-emulsifying composition
JP6783891B2 (ja) * 2019-04-10 2020-11-11 持田製薬株式会社 ω3脂肪酸の自己乳化組成物

Also Published As

Publication number Publication date
US20240165066A1 (en) 2024-05-23
IL314467A (en) 2024-09-01
EP4468884A4 (en) 2025-12-10
EP4468884A1 (en) 2024-12-04
AU2023213684A1 (en) 2024-08-15
KR20240142470A (ko) 2024-09-30
MX2024009147A (es) 2024-08-06
CA3248854A1 (en) 2023-08-03
MA66915A1 (fr) 2025-10-31
WO2023146984A1 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
JP2025503961A (ja) 脂肪酸のリンパ放出組成物並びにリンパ組み込み及び全身疾患治療のためのその使用
US11141399B2 (en) Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
Davidson Omega-3 fatty acids: new insights into the pharmacology and biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid
US12156860B2 (en) Disorders implicating PUFA oxidation
RU2755902C2 (ru) Концентрированные терапевтические фосфолипидные композиции
US20120214771A1 (en) Compositions for treatment of cardiometabolic disorders
Braeckman et al. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study)
ES2685703T3 (es) Composiciones enriquecidas en DPA de ácidos grasos omega-3 poliinsaturados en forma de ácido libre
KR20210066831A (ko) 공기 오염에 대한 노출에 의해 생긴 질환 및/또는 장애의 치료 또는 예방을 위한 조성물 및 방법
JP2019206552A (ja) 小児メタボリック症候群を治療する方法
CN108096235A (zh) 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
US9532962B2 (en) Medium-chain length fatty acids and glycerides as nephroprotection agents
US20150073050A1 (en) Co-administration of omeprazole and eicosapentaenoic acid or a derivative thereof
Al-Turkmani et al. Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis
JP2016501248A5 (https=)
WO2013169648A1 (en) Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
CN101500555A (zh) 包含非诺贝特和他汀的新型制剂及相关治疗方法
CN118714935A (zh) 淋巴释放的脂肪酸组合物以及其用于淋巴并入和全身性疾病治疗的用途
US20140287004A1 (en) Use of an Omega-3 Lipid-Based Emulsion Following Ischemic Injury to Provide Protection and Recovery in Human Organs
HK40056640A (en) Compositions and methods for treating or preventing diseases and/or disorders caused by exposure to air pollution
JP2016500055A (ja) トリグリセリドを低減させる方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260123